The effects of anti-CXCL12/CXCR4 therapies have been most extensively studied in hematological malignancies, in which monoclonal CXCR4 targeting antibodies such as Ulocuplumab, have been tested with varying results. The gene discussed is CXCL12; the disease is hematologic disorder.